Warren will soon reveal how to pay for Medicare for all

Senator Elizabeth Warren (D-MA), a presidential candidate, has said she will soon reveal how she plans to pay for a Medicare for all health system as part of her platform, Politico reported.

Warren was recently slammed by other candidates about her lack of a plan to pay for universal healthcare during the Oct. 15 Democratic debate.

Medicare for all as a concept has support from around half the country and numerous Democratic presidential candidates have adopted some version of universal healthcare as part of their platform.

“This is something I’ve been working on for months and months, and it’s got just a little more work until it’s finished,” Warren said of her plan on Oct. 20.

Warren, alongside presidential candidate Sen. Bernie Sanders (I-VT), previously sponsored a Medicare-for-all bill. Sanders suffered a heart attack and was treated with stent placement earlier this month. The health scare forced him to pause campaign events for a number of days, but he appeared in the most recent Democratic debate. Sanders has largely been seen as a leader among the Democratic candidates when it comes to healthcare reform, some polls have shown.

Sanders has admitted that taxes are likely to increase to fund Medicare for all, though most Americans will see lower healthcare bills under the plan.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.